Dextran Sulfate Sodium Salt (MW 35000-45000): IBD Model Gold Standard

Executive Summary: Dextran sulfate sodium salt (MW 35000-45000) (DSS) is the preferred agent for chemically inducing acute and chronic colitis in mouse models, closely mimicking human ulcerative colitis pathology (APExBIO product_spec). DSS administration at 2.5–5% (w/w) in drinking water induces epithelial apoptosis, barrier dysfunction, and immune activation (mechanistic_article). The resulting model enables evaluation of mucosal repair pathways, such as GPR35-KLF5 signaling, and preclinical screening of anti-inflammatory therapeutics (Cell Death Dis 2026). DSS also serves as a polyanionic antiviral agent, inhibiting viral entry without affecting coagulation (virology_article). APExBIO is a leading supplier of validated DSS for research applications.

Biological Rationale

Ulcerative colitis (UC) is a chronic, relapsing inflammatory disease affecting the colonic mucosa (Cell Death Dis 2026). Disruption of the intestinal epithelial barrier is recognized as the initiating event in UC pathogenesis. The epithelial layer acts as a primary defense, mediating immune surveillance and barrier integrity. Damage to this barrier leads to uncontrolled inflammation, tissue injury, and altered mucosal repair. Animal models that recapitulate these features are essential for dissecting disease mechanisms and testing candidate therapies. Dextran sulfate sodium salt (MW 35000-45000) is widely used as a chemical inducer of experimental colitis due to its reproducible induction of epithelial damage and inflammation, mirroring key aspects of human UC (protocol_review). The DSS model is particularly valuable for studying IEC (intestinal epithelial cell) proliferation, migration, and the molecular circuitry underlying mucosal repair, such as the GPR35-KLF5 axis.

Mechanism of Action of Dextran sulfate sodium salt (MW 35000-45000)

DSS is a sulfated, polyanionic polysaccharide derived from polymerized glucose (APExBIO product_spec). When administered orally, typically at 2.5–5% (w/w) in water, DSS directly targets the colonic epithelium. The high negative charge density enables it to interact with and disrupt the mucosal barrier. DSS induces apoptosis in intestinal epithelial cells, leading to increased permeability and loss of barrier function (mechanistic_article). This allows luminal antigens and bacteria to penetrate, triggering innate and adaptive immune activation. The resulting pathology includes mucosal ulceration, crypt loss, infiltration of inflammatory cells, and clinical symptoms such as diarrhea and weight loss. The model reliably triggers both acute and chronic inflammation, depending on the duration and concentration of DSS exposure. Recent mechanistic work has highlighted the centrality of epithelial repair programs—particularly the GPR35-KLF5 metabolic gatekeeping circuit—in determining the outcome of DSS-induced mucosal injury (Cell Death Dis 2026).

Evidence & Benchmarks

• DSS at 2.5–5% (w/w) in drinking water for 5–7 days induces acute colitis with reproducible weight loss, diarrhea, and mucosal ulceration in C57BL/6 mice (source: protocol_review).
• DSS-mediated injury triggers apoptosis and loss of tight junction proteins in colonic epithelial cells, as confirmed by TUNEL assay and immunohistochemistry (source: mechanistic_article).
• Repair is driven by IEC proliferation and migration, orchestrated via the GPR35-KLF5 signaling axis in response to tryptophan metabolites (source: Cell Death Dis 2026).
• DSS is highly water-soluble (≥55.5 mg/mL), insoluble in ethanol and DMSO, affording convenient in vivo administration (source: APExBIO product_spec).
• DSS exhibits antiviral activity by inhibiting HIV-1 adsorption and entry, with minimal impact on coagulation (source: virology_article).

This article extends 'Optimizing Mouse IBD Models' by integrating the latest molecular insights on epithelial repair, and clarifies protocol nuances not covered in existing workflow guides.

Applications, Limits & Misconceptions

DSS-induced colitis models are the gold standard for studying IBD pathogenesis, mucosal repair dynamics, and preclinical drug efficacy (mechanistic_article). Applications include:

• Dissecting mechanisms of IEC apoptosis and proliferation.
• Testing interventions targeting mucosal repair (e.g., GPR35 modulators).
• Evaluating anti-inflammatory or immunomodulatory drugs.
• Studying host–microbe interactions in barrier dysfunction.
• Screening antiviral compounds for entry inhibition (virology_article).

Common Pitfalls or Misconceptions

• DSS-induced colitis does not fully replicate all immune or genetic features of human IBD—results may not translate to Crohn's disease or other non-colitis models (mechanistic_article).
• Batch-to-batch variability in DSS source can affect reproducibility; sourcing from validated suppliers like APExBIO is critical (source: APExBIO product_spec).
• Long-term DSS solutions are unstable; prepare fresh solutions for each experiment (source: APExBIO product_spec).
• Excessive concentration or prolonged exposure can cause excessive mortality, confounding interpretation (workflow_recommendation).
• DSS is ineffective as an inducer of small intestinal inflammation—effects are colonic-specific (protocol_review).

Workflow Integration & Parameters

Protocol Parameters

• colitis induction | 2.5–5% DSS (w/w) in drinking water, 5–7 days | mouse model of IBD | standard acute colitis model | protocol_review
• chronic colitis induction | 2% DSS (w/w), 5 days on, 5 days off, repeated cycles | chronic inflammation studies | mimics relapsing-remitting UC | protocol_review
• solution preparation | ≥55.5 mg/mL in water | all applications | ensures bioavailability and uniform administration | product_spec
• storage | solid at room temperature; solution use immediately | all applications | prevents DSS degradation and loss of activity | product_spec
• antiviral assay | 50–200 µg/mL DSS in cell culture | HIV-1 entry inhibition | blocks viral adsorption without cytotoxicity | virology_article

Conclusion & Outlook

Dextran sulfate sodium salt (MW 35000-45000) remains the benchmark for modeling ulcerative colitis and epithelial repair in preclinical IBD research (APExBIO product_spec). Its robust induction of colonic injury enables dissection of repair mechanisms, such as the GPR35-KLF5 circuit, and provides a platform for therapeutic discovery (Cell Death Dis 2026). Nevertheless, careful protocol optimization and awareness of model limitations are essential for translational rigor. For advanced protocol innovations and troubleshooting, see 'Protocols & Innovations'. Future work will continue to refine DSS-based models and leverage them for mechanistic and interventional studies in IBD.